CMND Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.800

Open

0.800

VWAP

0.70

Vol

2.32M

Mkt Cap

3.42M

Low

0.645

Amount

1.62M

EV/EBITDA(TTM)

--

Total Shares

2.39M

EV

-8.97M

EV/OCF(TTM)

--

P/S(TTM)

--

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

Show More

Events Timeline

(ET)

2026-04-14

09:00:00

Global Markets Stabilize, Globalstar Enters Merger Agreement with Amazon

2026-04-14

07:40:00

Clearmind Medicine's CMND-100 Meets Primary Endpoint in Clinical Trial

2026-03-30 (ET)

2026-03-30

09:30:00

Clearmind Medicine Completes Treatment of 18 Participants in CMND-100 Trial

2026-03-19 (ET)

2026-03-19

09:00:00

Clearmind Medicine Advances CMND-100 Clinical Trial

2026-03-17 (ET)

2026-03-17

09:20:00

Clearmind Medicine Announces Six Patents in Hong Kong

News

NASDAQ.COM

03:04 AMNASDAQ.COM

PinnedClearmind Medicine's CMND-100 Trial Receives Positive DSMB Recommendation

Newsfilter

04-15Newsfilter

Clearmind Receives Positive Recommendation for CMND-100 Trial

Newsfilter

04-14Newsfilter

Clearmind's Drug Trial Achieves Primary Endpoint

NASDAQ.COM

03-31NASDAQ.COM

Clearmind Medicine Reports Positive Progress in AUD Drug Trial

Newsfilter

03-30Newsfilter

Clearmind Advances Clinical Trial for Alcohol Use Disorder

Newsfilter

03-27Newsfilter

Clearmind Files Patent Application in India for Next-Gen Psychedelic Compounds

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks under $5 likely to be bullish today

Intellectia · 30 candidates

Price: $0.50 - $5.00Rsi Category: moderatePrice Change Pct: >= $2.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00

Ticker

Name

Market Cap$

JE Cleantech Holdings Ltd

5.26M

Southland Holdings Inc

66.02M

ioneer Ltd

275.18M

Rezolve AI PLC

949.87M

Baozun Inc

121.73M

Skillsoft Corp

34.60M

Low float stock screener

Intellectia · 1484 candidates

List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Lion Group Holding Ltd

638.91K

La Rosa Holdings

711.55K

Erayak Power Solution Group Inc

831.04K

NewGenIvf Group Ltd

864.77K

Quhuo Ltd

948.08K

Biodexa Pharmaceuticals PLC

1.01M

Find stocks with low float

Intellectia · 2888 candidates

Region: USShares Outstanding: <= 150,000,000

Ticker

Name

Market Cap$

Aditxt Inc

2.59M

Greenwave Technology Solutions Inc

4.33M

Golden Heaven Group Holdings Ltd

5.19M

American Rebel Holdings Inc

3.47M

iPower Inc

5.62M

UTime Ltd

1.44M

Whales Holding CMND

Trading Trends

People Also Watch

Frequently Asked Questions

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 0.65 USD — it has decreased -28.57

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to -3.66M USD, increased 144.62

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to -2084949.00 USD, increased 64.76

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of April 16 2026.

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 3.42M USD.